Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Contributed by: PR Newswire

Tags

Curasight

More Like This

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

PR Newswire associated0

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

PR Newswire associated0

Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial